IMPALA Podcast Series

IMPALA Podcast Series – Subscribe via Spotify so you never miss an episode!

Sharon Havenhand and Jeremy Jones are the hosts of this new IMPALA Podcast Series, where they invite guest speakers to join them in discussing key topics  from the IMPALA space and share the impact it is having across the biopharmaceutical industry.

Check out the episodes below:

Episode 1: What is IMPALA?

  • In this episode Sharon and Jeremy are joined by Timothe Menard, Co-Founder of IMPALA and Mike Pelosi, Co-Chair of IMPALA’s Strategic Steering Committee and Co-Lead of the Education Work Product Team. Listen as we discuss what IMPALA is and what they are trying to achieve.
  • You’ll also get the chance to hear more about the current IMPALA work products, Tim and Mike’s vision for the future of IMPALA before they wrap up with how you can get involved!

Episode 2: The Data Driven Quality Professional

  • In this episode Sharon and Jeremy are joined by Mike Pelosi, Co-Chair of IMPALA’s Strategic Steering Committee and Co-Lead of the Education Work Product Team, Joanna North, Co-Lead of the Education Work Product Team and Roshan D’Souza, Member of the Education Work Product Team.
  • Listen as they delve into the industry-leading initiatives of the IMPALA Education Work Product Team and learn about what’s key to becoming a Data-Driven Quality Professional in the dynamic world of biopharma.

Publications

CPT: Pharmacometrics & Systems Pharmacology cover

Cross-company collaboration to leverage analytics for clinical quality and accelerate drug development: The IMPALA industry group

July 2021 – CPT Pharmacometrics & System Pharmacology
Ménard T, Young K, Siegel L, Emerson J, Studt R, Sidor L; IMPALA Industry Group. CPT Pharmacometrics Syst Pharmacol (2021).

Author: Timothé Ménard et al.

Completed Work Products

simaerep icon / logo

Open-source Package for Clinical Safety reporting

The goal of the Clinical Safety Reporting Work Product Team was to shift from manual source data verification (SDV) to a common analytics driven approach to detect Adverse event (AE) under-reporting in clinical trials. It is based on bootstrap resampling and was developed by Roche and is being  explored and utilised by Merck, Biogen, Pfizer and Bayer.

Here are the links to the Code repository and documentation.

Read the news article with testimonials here.

View the November 9, 2023 Webinar here or access the slide presentation here.

(Disclaimer: All work products published by the IMPALA Consortium are released “as is.” It is the user’s responsibility to validate any information/product. Any express or implied warranties, including those to the accuracy or completeness of any information published are disclaimed. In no event shall IMPALA be liable for any direct, indirect, incidental, special, exemplary, or consequential arising in any way out of the use and/or publication of this product.)

Work Product Team Leads: Ronojit Adyanthaya and Björn Koneswarakantha

Conferences

Case study – Leveraging analytics for remote clinical quality oversight

This case study, presented at the 2nd APEC – Asia-Pacific Economic Cooperation Roundtable Dialogue, discusses opportunities for Post-Pandemic Regulatory Innovation Convergence, such as how analytics can help detect and mitigate issues faster, reduce the burden of retrospective, time-consuming traditional QA activities and ultimately accelerate approval and patient access to innovative drugs. View the full presentation here.

RQA Workshop on Data Analytics

The goal of the RQA Workshop Work Product Team was to engage with Industry and Inspectors in an open dialog on how Data Analytics can be used to speed up Drug Development. The workshop took place at the RQA Conference in Brighton in November 2022, and resulted in lively discussion and wide-ranging ideas.

View the summary, write-up, and video here.

Work Product Team Leads: Joanne Donald and Timothe Menard

DIA Global 2023

The DIA Global Meeting held in Boston from June 25-29, 2023, brought together professionals from the pharmaceutical industry, regulatory agencies, and research organisations. IMPALA was grateful to have a great delegation of members and to have three sessions to showcase some of the work products the Consortium is focusing on. It also afforded the group a chance to connect in person for collaborative exchange and conversation. Click for details on the different sessions where IMPALA was represented.